Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Monday. $88.20 million flowed into the stock on the tick-up and $190.63 million flowed out of the stock on the tick-down, for a money net flow of $102.43 million out of the stock. Of all companies tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.55 for the day and closed at $36.26
A number of brokerages recently commented on PFE. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, November 16th. JPMorgan Chase & Co. set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, Berenberg Bank set a $36.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $39.45.
The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The firm has a market cap of $214,650.00, a P/E ratio of 10.23, a PEG ratio of 2.05 and a beta of 0.94.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.78%. The ex-dividend date of this dividend is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is currently 38.64%.
Pfizer declared that its board has initiated a stock repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.
In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares in the company, valued at $3,827,946. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Several large investors have recently made changes to their positions in PFE. BlackRock Inc. raised its holdings in shares of Pfizer by 2.8% in the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after buying an additional 12,183,218 shares during the last quarter. Mackenzie Financial Corp raised its holdings in Pfizer by 29,164.7% during the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock worth $415,878,000 after purchasing an additional 11,442,753 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Pfizer by 243.5% during the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after purchasing an additional 9,339,749 shares in the last quarter. Vanguard Group Inc. raised its holdings in Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. raised its holdings in Pfizer by 81.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock worth $691,583,000 after purchasing an additional 8,563,358 shares in the last quarter. 70.12% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Traders Sell Shares of Pfizer (PFE) on Strength (PFE)” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://stocknewstimes.com/2018/02/21/traders-sell-shares-of-pfizer-pfe-on-strength-pfe-2.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.